Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) have been given an average rating of “Hold” by the nineteen research firms that are presently covering the company. Four research analysts have rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $159.81.
A number of research analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. set a $200.00 price objective on Intercept Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday. JMP Securities restated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Sunday, November 6th. Robert W. Baird restated an “outperform” rating and set a $332.00 price objective on shares of Intercept Pharmaceuticals in a research report on Monday, November 7th. Cantor Fitzgerald restated a “sell” rating and set a $60.00 price objective on shares of Intercept Pharmaceuticals in a research report on Monday. Finally, Zacks Investment Research lowered Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 19th.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.25% during midday trading on Tuesday, reaching $124.15. The company’s stock had a trading volume of 271,899 shares. The stock’s market cap is $3.08 billion. The stock has a 50-day moving average price of $109.76 and a 200-day moving average price of $130.67. Intercept Pharmaceuticals has a 52-week low of $91.50 and a 52-week high of $177.93.
In related news, insider Lisa Bright sold 249 shares of the company’s stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $113.60, for a total transaction of $28,286.40. Following the completion of the sale, the insider now owns 18,209 shares of the company’s stock, valued at approximately $2,068,542.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CMO David Shapiro sold 1,350 shares of the company’s stock in a transaction dated Friday, December 2nd. The shares were sold at an average price of $99.75, for a total transaction of $134,662.50. Following the sale, the chief marketing officer now directly owns 42,922 shares of the company’s stock, valued at approximately $4,281,469.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,904 shares of company stock valued at $822,111. 9.20% of the stock is owned by corporate insiders.
Hedge funds have recently bought and sold shares of the stock. A.R.T. Advisors LLC purchased a new stake in Intercept Pharmaceuticals during the fourth quarter valued at $706,000. White Square Capital LLP purchased a new stake in Intercept Pharmaceuticals during the fourth quarter valued at $7,117,000. Marshall Wace LLP boosted its stake in Intercept Pharmaceuticals by 180.7% in the fourth quarter. Marshall Wace LLP now owns 102,360 shares of the biopharmaceutical company’s stock valued at $11,121,000 after buying an additional 65,892 shares during the period. FMR LLC boosted its stake in Intercept Pharmaceuticals by 0.3% in the fourth quarter. FMR LLC now owns 3,721,316 shares of the biopharmaceutical company’s stock valued at $404,321,000 after buying an additional 12,360 shares during the period. Finally, State Street Corp boosted its stake in Intercept Pharmaceuticals by 20.2% in the fourth quarter. State Street Corp now owns 751,027 shares of the biopharmaceutical company’s stock valued at $81,600,000 after buying an additional 126,011 shares during the period. 82.28% of the stock is owned by institutional investors and hedge funds.
This story was first posted by sleekmoney and is the property of of sleekmoney. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this story can be read at http://sleekmoney.com/intercept-pharmaceuticals-inc-icpt-receives-average-recommendation-of-hold-from-analysts/1660518.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/intercept-pharmaceuticals-inc-icpt-receives-average-recommendation-of-hold-from-analysts/1660518.html
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.